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Medication errors in patients with reduced creatinine
clearance are harmful and costly; however, most studies have
been conducted in large academic hospitals. As there are few
studies regarding this issue in smaller community hospitals,
we conducted a multicenter, retrospective cohort study in six
community hospitals (100 to 300 beds) to assess the
incidence and severity of adverse drug events (ADEs) in
patients with reduced creatinine clearance. A chart review
was performed on adult patients hospitalized during a
20-month study period with serum creatinine over 1.5mg/dl
who were exposed to drugs that are nephrotoxic or cleared
by the kidney. Among 109,641 patients, 17,614 had reduced
creatinine clearance, and in a random sample of 900 of these
patients, there were 498 potential ADEs and 90 ADEs. Among
these ADEs, 91% were preventable, 51% were serious, 44%
were significant, and 4.5% were life threatening. Of the
potential ADEs, 54% were serious, 44% were significant,
1.6% were life threatening, and 96.6% were not intercepted.
All 82 preventable events could have been intercepted by
renal dose checking. Our study shows that ADEs were
common in patients with impaired kidney function in
community hospitals, and many appear potentially
preventable with renal dose checking.
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Medication errors are common in hospitals. Between 44,000
and 98,000 Americans die each year because of medical errors
and about 1 million people are injured.1 The leading cause of
medical injury in hospitalized patients in the Harvard
Medical Practice Study was the use of drugs, accounting for
19.4% of injuries.2
Reduced creatinine clearance is not uncommon in
hospitalized patients, and it has important consequences.
One review found a rate of 1% on hospital admission, 2–5%
during hospitalization, and even higher rates of 4–15% in
patients with certain surgical procedures such as cardiopul-
monary bypass surgery.3 A 12-month study controlling for
alerts with computerized physician order entry (CPOE) in
place found 12% of alerts being associated with renal
insufficiency or electrolyte imbalance.4 Furthermore, reduced
creatinine clearance is associated with a 5.5 times higher risk
of dying than in patients without reduced creatinine
clearance.5
Adverse drug events (ADEs) can prolong the length of stay
(LOS) and increase costs in patients with reduced creatinine
clearance. A study found a mean adjusted increased LOS of
8.2 days and adjusted additional costs of $29,823 in patients
with acute renal insufficiency because of amphotericin B
therapy.6 It has been shown that clinical decision support
systems can reduce the prolonged LOS in patients with
reduced creatinine clearance.7 In a study including 97,151
medication orders in patients with reduced creatinine
clearance, guided medication dosing with clinical decision
support systems improved the appropriateness of dose by
13% and appropriateness of frequency by 24%.7 Further-
more, a randomized, cross-sectional trial in a university
hospital intensive care unit-setting in Belgium showed a
threefold reduction of medication prescription errors com-
paring patients with renal insufficiency in a setting with
CPOE combined with clinical decision support system with a
paper-based setting.8
These and other advantages of CPOE systems in improv-
ing care led to the formation of the Massachusetts Hospital
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CPOE Initiative, which was launched in 2005, with support-
ing legislation passed in spring 2006.9 Coordinated by the
Massachusetts Technology Collaborative (MTC) and the New
England Healthcare Institute in collaboration with the
Massachusetts Hospital Association and the Massachusetts
Council of Community Hospitals, the initiative has the goal
of implementing CPOE in all community hospitals across the
state within 4 years.
Relatively few data are available from community
hospitals on the frequency of renal insufficiency and the
use of nephrotoxic and renally excreted drugs. We therefore
assessed the baseline rate of renally impaired patients and
their ADE rates in six community hospitals before the
introduction of CPOE systems.
RESULTS
Among 109,641 admissions to the six study sites during the
observation period, 17,614 (16.1%) were among patients
with reduced creatinine clearance (creatinine 41.5 mg/dl).
The mean age of patients on admission was 63.2 years (range
mean 59.6–72.7 years; Table 1); there was a highly significant
difference among sites (Po0.001). Of patients overall, 58.1%
were women (range 47.2–67.6%, Po0.001 among sites) and
most patients were white (89.9%, Po0.001).
In contrast, patients admitted with reduced creatinine
clearance on average were 6.8 years older with a mean age of
75 years (range means 70.8–78.3), with a higher percentage
of male patients (57.1%) and a somewhat higher percentage
of Caucasian patients (92.2%).
In comparison, patients with reduced creatinine clearance
who suffered an ADE were significantly older than the general
patient population (mean age 70.3 years, range of means
63.5–75.3, Po0.001) but younger than the patient popula-
tion with reduced creatinine clearance only (Po0.001;
Table 2). Patients with reduced creatinine clearance and
ADE did not show a significant difference regarding gender
or race compared with other admissions with reduced
creatinine clearance.
During the study period, there were 592 incidents with a
rate of 65.8/100 admissions overall (95% confidence interval
(CI) 60.6–71.2/100 admissions; Table 3). Most were potential
ADEs (84.1%, 55.3/100 admissions) and 15.2% (n¼ 90) were
ADEs with a rate of 10.0/100 admissions (95% CI 8.1–12.2/
100 admissions). There were four medication errors (0.7%)
with little potential for harm. The ranges among the study
sites varied: the rate of ADEs ranged from 4.0 to 14.0/100
admissions (Po0.05) and potential ADEs from 43.3 to
81.3/100 admissions (Po0.001). One patient on site 1 had
two renal ADEs; all the other patients (n¼ 88) had one ADE
per patient. Analysis of incidents by type showed that a large
proportion of ADEs were judged preventable (91.1 versus
8.9% non-preventable) differing significantly among sites
(Po0.05). In addition, of 498 potential ADEs 96.6% were
not intercepted with a significant difference among sites
(Po0.05).
Evaluation of incidents by severity showed that most were
serious (ADEs 51.1%, potential ADEs 54.4%) or significant
(ADEs 44.4%, potential ADEs 44.0%; Table 4). Of ADEs
4.5% were life threatening (0.44/100 admissions, 95% CI
0.14–1.0), whereas 1.6% of potential ADEs were life
threatening (0.9/100 admissions, 95% CI 0.41–1.7). None of
the incidents was fatal. Almost all of the serious ADEs were
preventable (93.5%) and 50.0% of the life-threatening ADEs
were preventable. Most of the serious potential ADEs were
Table 1 | Admission characteristics: study population, sites 1–6 (1/1/2005 to 8/31/06)
Characteristic All patients (n=109,641),%a Site 1,% Site 2,% Site 3,% Site 4,% Site 5,% Site 6,%
P-value
among sites
Age,b mean (range) 63.2 (18–107) 72.7 (18–99) 61.9 (18–99) 59.6 (18–105) 64.6 (18–107) 66.7 (18–103) 59.6 (18–106) o0.001c
18–44 21.5 8.4 27.6 32.1 12.8 14.2 29.9 o0.001d
45–54 11.3 7.7 9.4 9.4 14.1 12.5 10.7
55–64 13.5 9.0 9.9 10.2 19.2 14.4 11.9
65–74 16.5 16.4 14.2 14.1 21.3 16.7 13.1
75–84 23.2 32.6 23.5 21.0 23.3 24.7 20.2
X85 14.0 25.9 15.4 13.2 9.3 17.5 14.2
Gender (%)
Female 58.1 62.2 63.6 67.6 47.2 58.9 60.3 o0.001d
Male 41.9 37.8 36.4 32.4 52.8 41.1 39.7
Race
Caucasian 89.9 92.9 93.0 95.0 88.4 86.8 85.9 o0.001d
Hispanic 2.6 0.8 0.8 0.4 1.2 6.3 6.9
Not recorded 2.6 2.4 1.2 0.7 5.7 0.8 1.5
African American 2.2 2.3 2.2 1.1 1.4 4.3 3.3
Other 1.5 0.9 1.2 1.8 2.2 0.7 1.1
Asian 1.1 0.5 1.6 1.0 1.1 1.1 1.3
Native American 0.1 0.2 0.0 0.0 0.0 0.0 0.0
aFor data protection reasons, only percentages are given.
bFor one patient at site 3 age was not recorded.
cOne-way analysis of variance.
dFisher’s exact test.
Kidney International (2009) 76, 1192–1198 1193
BL Hug et al.: ADEs in patients with reduced creatinine clearance o r ig ina l a r t i c l e
not intercepted (97.8%) and all life-threatening potential
ADEs were non-intercepted. All of the 82 preventable ADEs
could have been prevented by renal dose checking.
Of potential ADEs, nearly all (99.8%; 497/498) could have
been prevented by CPOE systems with decision support: 495
(99.4%) by renal dose checking, 1 (0.2%) by drug dose
suggestion, 1 (0.2%) by cumulative dose check; 1 potential
ADE (0.2%) was not preventable by CPOE. Analysis of the
preventable ADEs (n¼ 82) showed that most were caused by
the use of too high a dose of a renally cleared or nephrotoxic
drug in the presence of rising creatinine. Most ADEs were
worsened renal function, with 89% including a rising
creatinine. In 3.7%, bradycardia/hypotension and hypogly-
cemia occurred, with oversedation in 2.4% and nausea in
1.2%. The type of error was almost exclusively the choice of a
wrong dose in 86.6% or the wrong frequency in 12.2%.
Kappa statistics for inter-rater reliability showed an 88.4%
agreement for ADE versus no ADE (k¼ 0.46, 95% CI
0.36–0.56), 88.6% agreement for ADE versus potential ADE
or exclusion (k¼ 0.48, 95% CI 0.37–0.58), and 95.1%
agreement for preventable versus not preventable (k¼ 0.64,
95% CI 0.18–1.00).
Table 2 | Characteristics of admissions with reduced creatinine clearance including an ADE (n=89) and comparison with all
admissions with reduced creatinine clearance
Characteristic
All sites, n=89
(%; P-valuec)
Site 1, n=17
(%; P-valuec)
Site 2, n=16
(%; P-valuec)
Site 3, n=18
(%; P-valuec)
Site 4, n=21
(%; P-valuec)
Site 5, n=6
(%; P-valuec)
Site 6, n=11
(%; P-valuec)
Age, mean
((years), s.d.; P-valuec)d
70.3 (15.2; o0.001b) 72.3 (12.1; NSb) 72.6 (16.2; NSb) 75.3 (13.8; NSb) 63.5 (14.6;o0.05b) 65.0 (21.6; NSb) 71.8 (16.0; NSb)
18–44 6 (6.7; o0.05a) 0 (0; 0.05a) 1 (6.2; NSa) 1 (5.6; NSa) 2 (9.5; NSa) 1 (16.7; NSa) 1 (9.1; NSa)
45–54 7 (7.9) 1 (5.9) 1 (6.2) 0 3 (14.3) 2 (33.3) 0
55–64 16 (18.0) 3 (17.6) 3 (18.8) 2 (11.1) 5 (23.8) 0 3 (27.3)
65–74 19 (21.4) 7 (41.2) 1 (6.2) 5 (27.8) 5 (23.8) 0 1 (9.1)
75–84 23 (25.8) 3 (17.6) 5 (31.3) 5 (27.8) 5 (23.8) 2 (33.3) 3 (27.3)
X85 18 (20.2) 3 (17.6) 5 (31.3) 5 (27.8) 1 (4.8) 1 (16.7) 3 (27.3)
Gender
Female 37 (41.6; NSa) 7 (41.2; NSa) 6 (37.5; NSa) 12 (66.7; NSa) 4 (19.0; NSa) 2 (33.3; NSa) 6 (54.4; NSa)
Male 52 (58.4) 10 (58.8) 10 (62.5) 6 (33.3) 17 (81.0) 4 (66.7) 5 (45.6)
Race
Caucasian 82 (92.1; NSa) 17 (100; NSa) 16 (100; NSa) 16 (88.9; o0.05a) 17 (81.0;o0.05a) 5 (83.3; NSa) 11 (100; NSa)
African American 2 (2.2) 0 0 0 1 (4.8) 1 (16.7) 0
Hispanic 3 (3.4) 0 0 0 3 (14.3) 0 0
Other 2 (2.3) 0 0 2 (11.1) 0 0 0
ADE, adverse drug event; NS, not significant.
aFisher’s exact test.
bt-test (for mean age comparison between all patients with reduced creatinine clearance versus patients with reduced creatinine clearance including an ADE.
cP-values for comparison with all patients with reduced creatinine clearance.
dOne-way analysis of variance.
Table 3 | Frequency of incidents, by type
All sites
Comparison
Site 1 Site 2 Site 3 Site 4 Site 5 Site 6
Incident n (%)
Rate/100
admissionsb
across sitesc
P-value n (%)
Rate/100
admissions n (%)
Rate/100
admissions n (%)
Rate/100
admissions n (%)
Rate/100
admissions n (%)
Rate/100
admissions n (%)
Rate/100
admissions
ADEs 90
(15.2)
10.0
(8.1, 12.2)
o0.05 18
(13.1)
12.0
(7.3, 18.4)
16
(16.2)
10.7
(6.3,16.8)
18
(21.7)
12.0
(7.3,18.4)
21
(22.6)
14.0
(8.8, 20.9)
6
(6.5)
4.0
(1.6, 8.1)
11
(12.6)
7.3
(3.8, 12.6)
Preventable 82
(91.1)
9.1
(7.3, 11.2)
o0.05 15
(83.3)
10.0
(5.8, 15.9)
15
(93.7)
10.0
(5.8,15.9)
18
(100)
12.0
(7.3, 18.4)
20
(95.0)
13.3
(8.3, 20.1)
5
(83.3)
3.3
(1.2, 7.2)
9
(81.8)
6.0
(2.9, 10.8)
Non-preventable 8
(8.9)
0.9
(0.41, 1.65)
NA 3
(16.7)
2.0
(.50, 5.2)
1
(6.3)
0.7
(0.04,2.9)
0 0 1
(5.0)
0.7
(0.04, 2.9)
1
(16.7)
0.7
(0.04, 2.9)
2
(18.2)
1.3
(0.22, 4.1)
Pot. ADEs 498
(84.1)
55.3
(50.6, 60.3)
o0.001 119
(86.9)
79.3
(65.9, 94.5)
83
(83.8)
55.3
(44.3, 68.1)
65
(78.3)
43.3
(33.6, 54.7)
68
(73.1)
45.3
(36.4, 57.0)
87
(93.5)
58.0
(46.7, 71.1)
76
(87.4)
50.7
(40.1, 62.9)
Non-intercepted 481
(96.6)
53.4
(48.8, 58.4)
o0.05 113
(95.0)
75.3
(62.3, 90.0)
80
(96.4)
53.3
(42.5, 65.9)
63
(96.9)
42.0
(32.5, 53.2)
67
(98.5)
44.7
(34.8, 56.2)
84
(96.5)
56.0
(44.9, 68.8)
74
(97.4)
49.3
(39.9, 61.4)
Intercepted 17
(3.4)
1.9
(1.1, 2.9)
NS 6
(5.0)
4.0
(1.6,8.1)
3
(3.6)
2.0
(0.50,5.2)
2
(3.1)
1.3
(0.22, 4.1)
1
(1.5)
0.7
(0.04, 2.9)
3
(3.5)
2.0
(0.50, 5.2)
2
(2.6)
1.3
(0.22, 4.1)
Medication
errorsa
4
(0.7)
0.4
(0.14,1.0)
NA 0 0 0 0 0 0 4
(4.3)
2.7
(0.83, 6.2)
0 0 0 0
Total 592
(100)
65.8
(60.6, 71.2)
137
(100)
91.3
(76.9, 107.5)
99
(100)
66.0
(53.8, 79.9)
83
(100)
55.3
(44.3, 68.1)
93
(100)
62.0
(50.2, 75.5)
93
(100)
62.0
(50.2,75.5)
87
(100)
58.0
(46.7, 71.1)
NA, not applicable; NS, not significant; Pot., potential.
aMedication errors with little potential for harm.
bAdmissions with reduced creatinine clearance.
cw2-test for equal rates across sites.
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Antibiotics ranked first regarding drugs involved in ADEs:
37% of preventable and 42.9% of non-preventable ADEs
were caused by antibiotics; most classes of antibiotics such as
penicillins, aminoglycosides, cephalosporins, and macrolides
were affected (Table 5). Analgesics ranked second causing
31.5% of preventable and 21.4% of non-preventable ADEs. In
this class, acetaminophen alone or as a compound drug and
opiates with derivates was most frequent. Cardiovascular
drugs ranked third causing 16.3% of preventable and 28.6%
of non-preventable ADEs. Angiotensin-converting enzyme -
inhibitors, antiarrhythmics, and diuretics were the most
frequent drugs in this category. Antifungal, oral antidiabetic,
and neurotropic agents caused each o5% of ADEs.
The diagnosis-related group-weighted LOS of all patients
at the study centers was higher than that of the national
average (þ 0.20 days; Pp0.001).10 Patients admitted with
Table 4 | Incidents, by preventability and severity
Incident All sites
ADEs
n (%) Rate/100 admissions (95% CI) Non-preventable, n (%) Preventable, n (%)
Significant 40 (44.4) 4.4 (3.2–6.0) 3 (7.5) 37 (92.5)
Serious 46 (51.1) 5.1 (3.8–6.7) 3 (6.5) 43 (93.5)
Life threatening 4 (4.5) 0.44 (0.14–1.0) 2 (50.0) 2 (50.0)
Total 90 (100.0) 10.0 (8.1–12.2) 8 (8.9) 82 (91.1)
Potential ADEs
Non-intercepted, n (%) Intercepted, n (%)
Significant 219 (44.0) 24.4 (21.4–27.8) 208 (95.0) 11 (5.0)
Serious 271 (54.4) 30.1 (26.7–33.8) 265 (97.8) 6 (2.2)
Life threatening 8 (1.6) 0.9 (0.41–1.7) 8 (100) 0
Total 498 (100.0) 55.3 (50.6–60.3) 481 (96.6) 17 (3.4)
ADE, adverse drug event.
Table 5 | Drug classes involved in ADEs
Number of drugs
involved in ADEs,
preventable
Number of drugs
involved in ADEs,
non-preventable Drugs
Drug class Total, n (%) Total, n (%)
Antibiotics 100 (37.0) 6 (42.9) Ampicillin (and sulbactam), cefaclor, cefazolin, cefotaxime, ceftazidime, cefuroxime
axetil, ciprofloxacin, erythromycine, gatifloxacin, gentamycin sulfate, imipenem,
levofloxacin, metronidazole, penicillin G, piperacillin and tazobactam sodium,
trimethoprim-sulfomethoxazole, tobramycin sulfate, vancomycin.
Analgesics 85 (31.5) 3 (21.4) Acetaminophen, codeine and acetaminophen, hydrocodone, ketorolac,
meperidine, morphine (sulfate), oxycodone and acetaminophen, propoxyphene
and acetylic salicylic acid and acetaminophen.
Non-narcotic,
non-NSAID*
45 (53.0) 1 (33.3)
1 (33.3)
Narcotic 39 (45.9)
NSAID 1 (1.1) 1 (33.3)
Cardiovascular 44 (16.3) 4 (28.6) Atenolol, bumetanide, captopril, digoxin, enalapril, hydralazine,
hydrochlorothiazide, lisinopril, sotalol, spironolactone, quinapril.
ACE inhibitors 24 (54.5) 2 (50.0)
Antiarrhythmics 11 (25.0) —
Diuretics 6 (13.6) 1 (25.0)
b-Blockers 3 (6.8) 1 (25.0)
Diabetes 12 (4.4) — Glipizide, glyburide, metformin.
Oral antidiabetics 12 (100) —
Antifungal agents 11 (4.1) — Fluconazole
Neurotropic drugs 2 (0.7) — Lithium, midazolam
Sedatives 1 (50.0) —
Antipsychotics 1 (50.0) —
Other drugs 16 (5.9) 1 (7.1) Allopurinol, colchicine, famotidine, ranitidine, sucralfate.
Gastrointestinal 9 (56.2) —
Anti-gout 5 (31.3) —
Unknown 2 (12.5) 1 (100)
Total no. of drugs 270 (100) 14 (100)
ACE inhibitors, angiotensin-converting enzyme inhibitors; ADE, adverse drug event; NSAID, non-steroidal anti-inflammatory drugs.
Kidney International (2009) 76, 1192–1198 1195
BL Hug et al.: ADEs in patients with reduced creatinine clearance o r ig ina l a r t i c l e
reduced creatinine clearance showed an additional average
LOS of þ 2.28 days compared with other patients at the
study sites (Table 6; groups C versus B, P¼o0.001). Patients
admitted with reduced creatinine clearance who suffered an
ADE stayed on average additional 5.21 days compared with
the patients with reduced creatinine clearance alone (groups
D versus C, P¼o0.001) and þ 7.49 days compared with all
the admissions during the study period at the six study
centers (groups D versus B, P¼o0.001).
DISCUSSION
We found that one in 10 patients with baseline renal
insufficiency suffered an ADE in this community hospital
population. For every ADE, there were about five potential
ADEs. Of all renal ADEs, nine of 10 were considered
preventable. Half of the life-threatening ADEs were con-
sidered preventable. The prevention strategy with the greatest
potential benefit was renal dose checking. ADEs were
associated with a substantial prolongation of LOS.
Overall, ADE rates including ADEs of all types, not just
renal ADEs, in one study were 6.5/100 admissions in an
academic tertiary referral hospital in the same region.11 By
contrast, in this study there were about 1.5 renal ADEs per
100 admissions. In another study, in this population reported
elsewhere, we found an ADE rate of 15.0/100 admissions
(Hug BL LS1 et al., unpublished data). Kilbridge et al.12 have
reported previously that ADEs differ somewhat regarding
frequency and quality between community hospitals and
tertiary referral hospitals. However, relatively speaking, few
data are available assessing the frequency of ADEs in commu-
nity hospitals and more evaluations would be helpful.
In addition to the overall high preventability of ADEs, all
the preventable ADEs might have been potentially preven-
table by renal dose checking, a measure that can relatively
easily be introduced into existing CPOE systems. Chertow
et al. found that an inexpensive decision support system
added to CPOE significantly improved drug dosing in
patients with renal insufficiency, although there was still
substantial room for improvement.13 The same study showed
a reduction of the LOS of 0.5 days for patients with renal
insufficiency. In another study of psychotropic medication
use in a geriatric population, when clinical decision support
was delivered, agreement with recommended dosing guide-
lines improved by 34% and the fall rate fell significantly.14
Rind et al.15 showed that using physician alerts in patients
with rising serum creatinine levels invoked a faster physician
reaction regarding drug choice and dose adaptation, reduced
the risk of serious renal impairment by 55%, preserved renal
function and was well accepted by the physicians involved.
Furthermore, Nash et al.16 found that implementing an
automated system to complement an existing CPOE system
made the baseline rate of excessive dosing in patients with
renal impairment decrease from 23.6 to 17.3%.
In this study, antibiotics, analgesics, and cardiovascular drugs
were most frequently involved in causing ADEs. The list of
drugs potentially causing acute renal insufficiency is long:
affecting renal hemodynamics (e.g., non-steroidal anti-inflam-
matory drugs, nonsteroidal anti-inflammatory drugs), direct
tubular toxicity (e.g., aminoglycosides), intratubular obstruc-
tion-like sulfonamides and certain human immunodeficiency
virus drugs (e.g., indinavir), as well as allergic interstitial
nephritis (e.g., penicillins, cephalosporins, diuretics).12,13 Classen
et al.17 found a similar array of culprit drugs, namely, analgesics
(morphine and derivates, acetaminophen), antiarrhythmic
drugs (digoxin), antibiotics (imipenem, cefazolin, vancomycin),
as well as meperidine and warfarin. Gandhi et al.18 found in
their analysis of 181 ADEs in an ambulatory setting that 10%
were caused by selective serotonin reuptake-inhibitors, 9% by
b-blockers, 8% each by angiotensin-converting enzyme inhibi-
tors and nonsteroidal anti-inflammatory drugs.
Adverse drug events in patients with impaired renal
clearance are dangerous and prolong the LOS. Our results
showed a highly significant excess LOS of patients with
reduced creatinine clearance (þ 2.28 days) and additionally
through suffering an ADE (þ 5.21 days) compared with the
average of all patients. Although these numbers may seem
high, a study on cost and nephrotoxicity of amphotericin B
showed very similar results: Bates et al.6 found that in the
case of acute renal insufficiency in patients exposed to
amphotericin B the mean adjusted increase in LOS was 8.2
days. In patients with reduced creatinine clearance and ADE
LOS is higher compared with patients with ADEs in general.
Overall, Classen et al. found an adjusted additional increase
in LOS of 1.91 days in patients with ADEs,16 while Bates et al.
showed an increase of LOS of 2.2 days and for preventable
ADEs the increase of LOS was 4.6 days.19
Table 6 | Length of stay: patients with renal insufficiency and ADEs in comparison with other admissions
Total no. of
admissions
Attributable length of stay,
mean (s.d.)
Overall,
range
Range among
6 sitesb Difference (P-valuec)
A. DRG-weighted national average LOS (109,641a) 4.60 (3.09) 0–42.9 4.0–5.1 Reference
B. All admissions study centers 109,641 4.80 (5.35) 0–276 3.9–6.0 +0.20d
C. Admissions with reduced creatinine
clearance
17,614 7.08 (7.25) 0–115 5.8–7.8 To A: +2.48d B: +2.28d
D. Admissions with reduced creatinine
clearance and ADE
90 12.29 (9.85) 1–46 6.9–15.0 To A: +7.69d B: +7.49d
C: +5.21d
ADE, adverse drug event; DRG, diagnosis-related group; LOS, length of stay.
aDRG adjusted to group B; DRG-weighted LOS could be obtained for 99.43% of patients.
bRange of site average.
ct-test.
dPo0.001.
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Our study has several limitations. Patient populations
might show differences between hospitals on the basis of age
and case mix. We therefore averaged results among the six
community hospitals. Furthermore, patients were mainly
Caucasian and results in hospitals with more minority
patients might have different results. Although random
sampling with trigger tools is a widely acknowledged way
of measuring safety and specifically ADE incidence in
hospitals on wards as well as intensive care units,20 it may
not represent all ADEs occurring at a test site. To our
knowledge, although, it is to date the best way to balance
cost, time-consumption, and effectiveness detecting ADEs in
institutions without any CPOE or electronic medical records
in place, and is especially well suited to assess renal ADEs
because of the accessibility of creatinine. As in many cases we
did not have the complete renal history at our disposal, it was
not possible to discern between acute, chronic, or acute on
chronic renal failure. In addition, most of the ADEs were
increases in creatinine, and we could not be certain that they
were related to the nephrotoxic medications being given in
any specific instance, so that other factors may have caused
some of the elevations in creatinine. Assessment of presence
of ADEs was based on reviewer judgment, and agreement was
not complete. However, our inter-rater reliability was
comparable with earlier studies.11 In some of the study sites
CPOE systems were about to be implemented, which might
have caused a higher awareness of the medical staff regarding
drug safety issues compared with other sites. The study sites
are located in one state in the northeast; the results may
therefore not be generalizable to other regions.
In summary, we found that ADEs were common in
patients with reduced creatinine clearance and that they
prolonged hospital stays. Most are likely preventable with
renal dose checks combining laboratory values with phar-
macy databases. Although the rates of renally related ADEs
varied somewhat by hospital, all would benefit by introdu-
cing this decision support.
MATERIALS AND METHODS
Study design
We conducted a retrospective cohort study with chart review of
admissions within the period from 1 January 2005 until 31 August
2006. The Brigham and Women’s Hospital Institutional Review
Board, as well as the local review boards of all study sites approved
the investigation.
Study centers
The study centers were six community hospitals in Massachusetts
with 100 to 300 beds; three had house staff, and three did not.
Patient population
All hospitalized patients from the six study sites were included
during the study period accounting for a total of 109,641
admissions. Patients were defined as having reduced creatinine
clearance at baseline be it acute or chronic if they had a creatinine of
1.5 mg/dl or higher. The study included 17,614 (16.1%) admissions
of patients with acute or chronic reduced creatinine clearance.
Case finding and definitions. All patients with a creatinine over
1.5 mg/dl measured on first occurrence during the study period and
exposed to potentially nephrotoxic or renally cleared drugs were
identified from the population of all patients hospitalized during the
observation period. Duration of reduced creatinine clearance was not
known; therefore chronic, acute, and acute on chronic renal failure
were all likely present in the study population, although we suspect
chronic kidney disease predominated. A random number generator
was used to select 150 admissions from each of the six study sites.
To assess the level of renal function, trained study nurses
obtained body weight and height measurements from the charts,
and renal clearance was computed according to Cockroft–Gault
((140 – age)  weight/serum creatinine  72, correction factor of
0.85 for women).21 Subsequently, patients were stratified into three
levels of renal insufficiency: level 1 with creatinine clearance of
o15 ml/min, level 2 with 15–50 ml/min, and level 3 with 50–80 ml/min.
Creatinine clearance above 80 ml/min was considered normal. The
study then followed the dosage guidelines for all three levels of renal
insufficiency as developed previously at the Brigham and Women’s
Hospital, Boston.7
Trained study nurses identified incidents that suggested a
medication error or ADE using the Institute of Healthcare
Improvement trigger tool as described by Rozich et al.22,23 Each
incident was independently reviewed by two physicians and
classified according to type, severity, and preventability as published
elsewhere.11,24,25 In brief, an incident was first classified as to
whether or not it was a medication error, a potential ADE or an
ADE. An incident was defined as any irregularity in the process of
medication use, a general term before classification into medication
error, ADE, or neither of both.24 A medication error was defined as
an error in the process of ordering or delivering a medication,
regardless of whether an injury occurred or not.25 An ADE was
defined as an injury related to a drug; a potential ADE was defined
as medication error with the potential for injury, but in which no
injury occurred.25 Second, incidents were reviewed for severity as
significant (e.g., rash), severe (e.g., gastrointestinal bleed), life
threatening (e.g., transferal to intensive care unit), or fatal.26 To
stratify the extent of reduced creatinine clearance, we used the
Bonney Criteria: an increase o10% of patient creatinine was
considered a potential ADE, an increase of 10–100% a significant
ADE and more than 2 baseline creatinine a serious ADE.27
Increases in creatinine were considered ADEs only for drugs with
nephrotoxicity, and not for renally excreted drugs. Third, prevent-
ability was classified as probably preventable, definitely preventable,
probably not preventable and definitely not preventable.28 Prevent-
ability was consequently collapsed into preventable (probably and
definitely preventable) or not preventable (probably and definitely
not preventable). In case of disagreement regarding type, severity, or
preventability of the incident, the physician reviewers met for
reconciliation. If consensus could not be reached a third party
reviewer evaluated the incident. Kappa statistics for inter-rater
reliability were then computed. Judgment of potential preventability
by CPOE systems was made implicitly, but these judgments were
grounded by earlier studies that documented an error reduction
when CPOE was implemented, for example, regarding dose,
frequency, route of application, drug substitution, allergy, avoidable
delay, and drug–drug interactions.29
Main outcome measures
The main outcome measures were incidence, type, severity, and
preventability of ADEs before introduction of CPOE systems and
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the estimation of potential benefit in diagnosis-related group-
weighted LOS compared with former studies.19
Average LOS
Average LOS per patient was computed. These were weighted by
diagnosis-related group for all admitted patients. Patients with
reduced creatinine clearance and ADEs were compared with the
national average and those with reduced creatinine clearance who
did not suffer an ADE.
Data analysis
All categorical variables are reported as percentages in summary
statistics. For comparison of categorical variables, we used w2 and
Fisher’s exact test, for comparison of means the t-test and the
analysis of variance procedure. As threshold of statistical significance
we used an a¼ 0.05. For statistical analysis we used the SAS 9.1
package (SAS Institute, Cary, NC).
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